Pyxis Oncology Reports 36% Response Rate in Phase 1 MICVO Study

08:26 AM EDT, 09/09/2026 (MT Newswires) -- Pyxis Oncology (PYXS) reported a 36% confirmed response rate and 94% disease control rate in updated phase 1 data for micvotabart pelidotin in second-line and beyond recurrent/metastatic head and neck cancer, the company said Wednesday. The company said median progression-free survival was 6.2 months and the 12-month overall survival probability was 79%, with activity across key subgroups and no new safety signals. Pyxis added the data support advancing MICVO to phase 3, with the Headliner trial planned for mid-2027 to enroll about 500 patients and compare MICVO with investigators' choice of cetuximab, docetaxel, or methotrexate. The company expects updated monotherapy OS data in H1 2027 and additional MICVO/KEYTRUDA combination data in Q4 2026, it added. Pyxis Oncology shares were down 10% in premarket activity.